Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
28.75
+0.41 (1.45%)
May 26, 2026, 4:00 PM EDT - Market closed
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $8.21M in the quarter ending March 31, 2026, a decrease of -12.80%. This brings the company's revenue in the last twelve months to $71.10M, up 121.11% year-over-year. In the year 2025, Assembly Biosciences had annual revenue of $72.30M with 153.52% growth.
Revenue (ttm)
$71.10M
Revenue Growth
+121.11%
P/S Ratio
7.78
Revenue / Employee
$973,932
Employees
73
Market Cap
553.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.30M | 43.78M | 153.52% |
| Dec 31, 2024 | 28.52M | 21.36M | 298.16% |
| Dec 31, 2023 | 7.16M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 6.25M | -72.85M | -92.09% |
| Dec 31, 2020 | 79.11M | 63.14M | 395.55% |
| Dec 31, 2019 | 15.96M | 1.16M | 7.83% |
| Dec 31, 2018 | 14.80M | 5.79M | 64.14% |
| Dec 31, 2017 | 9.02M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Rigel Pharmaceuticals | 299.77M |
| Ginkgo Bioworks Holdings | 151.40M |
| Gyre Therapeutics | 117.05M |
| Prime Medicine | 4.03M |
| ProKidney | 889.00K |
| Altimmune | 36.00K |
ASMB News
- 16 hours ago - Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 days ago - Assembly Biosciences announces expansion of ABI-6250 clinical development - TheFly
- 5 days ago - Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 days ago - Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - GlobeNewsWire
- 13 days ago - Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference - MarketBeat
- 13 days ago - Assembly Biosciences Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 - GlobeNewsWire
- 16 days ago - Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference - GlobeNewsWire